---
title: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant
  chemotherapy in PDAC
date: '2023-09-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37679568/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230908181252&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Neoadjuvant chemotherapy can improve the survival of individuals with
  borderline and unresectable pancreatic ductal adenocarcinoma; however, heterogeneous
  responses to chemotherapy remain a significant clinical challenge. Here, we performed
  RNA sequencing (n = 97) and multiplexed immunofluorescence (n = 122) on chemo-naive
  and postchemotherapy (post-CTX) resected patient samples (chemoradiotherapy excluded)
  to define the impact of neoadjuvant chemotherapy. Transcriptome analysis combined
  ...
disable_comments: true
---
Neoadjuvant chemotherapy can improve the survival of individuals with borderline and unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to chemotherapy remain a significant clinical challenge. Here, we performed RNA sequencing (n = 97) and multiplexed immunofluorescence (n = 122) on chemo-naive and postchemotherapy (post-CTX) resected patient samples (chemoradiotherapy excluded) to define the impact of neoadjuvant chemotherapy. Transcriptome analysis combined ...